Navigation Links
IDEXX Laboratories Announces Second Quarter Results
Date:7/24/2009

WESTBROOK, Maine, July 24 /PRNewswire-FirstCall/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), today reported that revenues for the second quarter of 2009 were $265.7 million compared to $280.6 million for the second quarter of 2008. Organic revenue growth, as defined below, was 5%. Earnings per diluted share ("EPS") for the quarter ended June 30, 2009 were $0.55 compared to $0.63 for the same period in the prior year. Excluding incremental EPS that resulted from sales of pharmaceutical products that were subsequently divested or discontinued in 2008, EPS in the second quarter of 2008 would have been $0.54, and thus EPS growth without this contribution was 2%.

Organic revenue growth excludes the impact of changes in currency exchange rates, which reduced revenue growth by approximately 5%, and revenue from businesses acquired or divested subsequent to the beginning of the prior year period, including pharmaceutical products that were divested in the fourth quarter of 2008. Pharmaceutical revenues and related earnings in the second quarter of 2008 were exceptionally high due to the sale of the remaining inventory of PZI VET((R)) in connection with the discontinuation of that product.

"Our second quarter results reflect our continued focus on productivity in the current economic environment," said Jonathan Ayers, Chief Executive Officer. "Economic weakness reduced pet visits to U.S. veterinary clinics, our largest customer segment, by an estimated 4% year over year, similar to the first quarter of 2009. We nonetheless achieved 5% organic growth during the period. This growth was led by sales of our Catalyst Dx((R)) chemistry analyzers and consumables, which transitioned out of limited launch phase and into full commercialization in the second quarter, per our expectation. We are very pleased with customer adoption
'/>"/>

SOURCE IDEXX Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine news :

1. IDEXX Laboratories to Release 2009 Second Quarter Financial Results
2. IDEXX Laboratories to Present at William Blair 29th Annual Growth Stock Conference
3. IDEXX Laboratories Announces First Quarter Results
4. IDEXX Laboratories to Release 2009 First Quarter Financial Results
5. IDEXX Laboratories Announces Fourth Quarter and Full Year Results
6. IDEXX Laboratories to Release 2008 Fourth Quarter and Full-Year Financial Results
7. IDEXX Laboratories Names William Brown Corporate Vice President
8. IDEXX Laboratories to Present at William Blair 28th Annual Growth Stock Conference
9. IDEXX Laboratories to Release 2008 First Quarter Financial Results
10. IDEXX Laboratories Announces Increase in Share Repurchase Program
11. IDEXX Laboratories Announces Fourth Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... Professional Background Screeners (NAPBS®) has announced that Edge Information Management has ... by the Background Screening Credentialing Council (BSCC). , ÔÇťAchieving and maintaining ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider of ... signs and activity, today announced its integration with leading veterinary Practice Management Software ... veterinary hospital Practice Management Software packages in the US. Practice Management Software helps ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... government entities, announced today that it has hired Scott Sanderson, an experienced business ... this capacity, Sanderson will be responsible for establishing and managing new client relationships ...
(Date:9/1/2015)... ME (PRWEB) , ... September 01, 2015 , ... Royal ... large, new study that followed men and women for 19 years and found that, ... who did not take multivitamins. , The report is part of the September 2015 ...
Breaking Medicine News(10 mins):Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2
... AEGON N.V.,and the international humanitarian organization Right ... the organization,s mission to help,children in deprived areas ... donated EUR 1 million as part of a ... Winter Olympic games in Vancouver, Canada., (Photo: ...
... benefit from further study of vitespen, researchers say , , ... vitespen didn,t increase recurrence-free survival among kidney cancer patients ... standard treatment for kidney cancer, but many patients are ... effective adjuvant treatment, according to background information in the ...
... at work, one expert says , , THURSDAY, July 3 (HealthDay ... man,s chances of developing erectile dysfunction, Finnish researchers report. , ... body. It,s what we in vascular surgery refer to as ... Sadeghi-Nejad, an associate professor of urology at UMDNJ New Jersey ...
... director of the National Alliance on Mental Illness ... the lives,of individuals and families affected by mental ... monitor the callous treatment and tragic death of,Ms. ... the psychiatric,ward at Kings County Hospital in Brooklyn, ...
... Renowned stroke researcher Dr. Vladimir Hachinski has been named ... for his lifetime contributions in the field of neurology. ... University of Western Ontario in the Department of Clinical ... Dentistry. He is the founding and current chairman ...
... is a condition that unexpectedly and unexplainably takes the lives ... year. Now researchers of the European Molecular Biology Laboratory in ... crib or cot death, which remains the leading cause of ... The model, published in this week,s issue of Science ...
Cached Medicine News:Health News:AEGON and Right To Play Announce Global Partnership 2Health News:AEGON and Right To Play Announce Global Partnership 3Health News:Kidney Cancer Vaccine Shows No Boost in Survival 2Health News:Lots of Sex May Prevent Erectile Dysfunction 2Health News:Kings County Death: NAMI Calls for Criminal Probe; Survey Shows Psychiatric Emergency Room Delays Are National Problem 2Health News:Pioneering stroke researcher awarded Canada's highest honor 2Health News:New research sheds light on the molecular basis of crib death 2
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
Medicine Products: